Covidien has announced it has received FDA clearance for its LigaSure curved, small jaw, open sealer/divider surgical instrument to be used in ENT procedures, according to a news release.
The LigaSure small jaw instrument was previously cleared for use in general surgery by FDA in February 2011. The new clearance will allow for additional uses such as thyroidectomies, parotidectomies and additional open ENT procedures.
"This is a major milestone in recognizing the LigaSure small jaw instrument as an effective open surgical device and significantly expands its use throughout the surgical community. We believe surgeons will see it as a valuable tool for ENT procedures," said Bryan Hanson, group president, surgical solutions for Covidien, in the release. "LigaSure technology has set the industry standard in vessel sealing since 1998. This technology has been used in millions of surgical procedures worldwide and is supported by an every growing body of evidence-based research."
The LigaSure instrument features an integrated cutting mechanism and a multifunctional design for blunt dissection, according to the company. It is powered by the ForceTriad energy platform, providing surgeons with continuous output of energy, monitoring the tissue and making real-time adjustments 3,333 times/second to seal vessel walls.
Covidien has its U.S. headquarters in Mansfield, Mass.
Related Articles on FDA Clearances:
Preventice Receives FDA Clearance for Remote Monitoring System
Siemens Receives FDA Clearance for Digital Radiography System
OptiMedica Receives FDA Clearance for Corneal Incisions With Catalys System